公开(公告)号：US10669587B2

公开(公告)日：2020-06-02

申请号：US16295536

申请日：2019-03-07

Applicant: GENENTECH, INC.

Inventor： Jason A. Hackney ,  Mary Keir ,  Gaik Wei Tew

IPC: C12Q1/6883 ,  C07K16/28 ,  A61K39/00

Abstract: Biomarkers predictive of responsiveness to integrin beta7 antagonists, including anti-beta7 integrin subunit antibodies, and methods of using such biomarkers are provided. In addition, methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of using such predictive biomarkers for the treatment of inflammatory bowel diseases including ulcerative colitis and Crohn's disease.

公开(公告)号：US20200155676A1

公开(公告)日：2020-05-21

申请号：US16453650

申请日：2019-06-26

Applicant: Genentech, Inc.

Inventor： Jane GROGAN ,  Yuanyuan XIAO ,  Patrick CAPLAZI ,  Steve LIANOGLOU ,  Jason HACKNEY ,  Eugene Yu-Chuan CHIANG

IPC: A61K39/395 ,  C07K16/28 ,  C07K16/24 ,  A61K47/62 ,  C07K16/30

Abstract: The present disclosure provides methods comprising administering to the individual an effective amount of a PD-1 axis binding antagonist and an IL-17 binding antagonist. Further provided are kits comprising a PD-1 axis binding antagonist, an IL-17 binding antagonist, or both, as well as instructions for use thereof.

公开(公告)号：US10654867B2

公开(公告)日：2020-05-19

申请号：US16565041

申请日：2019-09-09

Applicant: Genentech, Inc.

Inventor： Sharada Labadie ,  Jun Li ,  Jun Liang ,  Daniel Fred Ortwine ,  Xiaojing Wang ,  Jason Zbieg ,  Birong Zhang ,  Nicholas Charles Ray ,  Simon Goodacre ,  Jiangpeng Liao

IPC: A61K31/4985 ,  A61K31/397 ,  C07D495/04 ,  C07D491/048 ,  A61K31/4355 ,  A61K45/06 ,  A61K31/4365 ,  C07D487/04 ,  C07F7/18 ,  C07D471/04 ,  A61K31/437 ,  C07D471/14 ,  A61K31/4375 ,  A61K31/695 ,  A61K31/55

Abstract: Described herein are heteroaryl compounds with estrogen receptor modulation activity or function having the Formula I, II, and III structures: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I, II, and III compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

公开(公告)号：US20200148756A1

公开(公告)日：2020-05-14

申请号：US16579419

申请日：2019-09-23

Applicant: Genentech, Inc.

Inventor： Rajeshwari Swamy ,  Julie Hambleton

IPC: C07K16/22 ,  A61K31/7068 ,  A61K31/337 ,  A61P35/00 ,  A61K31/475 ,  A61P35/04 ,  A61K45/06 ,  A61K39/395

Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, in combination with one or more additional anti-tumor therapeutic agents in previously treated metastatic breast cancer.

公开(公告)号：US10604557B2

公开(公告)日：2020-03-31

申请号：US15357545

申请日：2016-11-21

Applicant: Genentech, Inc.

Inventor： Sunil Bhakta ,  Jagath R. Junutula

IPC: A61K39/395 ,  C07K16/30 ,  C07K16/28 ,  A61K47/48 ,  A61K39/00 ,  G01N33/574 ,  C07K16/00 ,  A61K51/10 ,  A61K47/68 ,  C07K16/32

Abstract: Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody. Certain highly reactive cysteine engineered antibodies were identified by the PHESELECTOR assay. Isolated cysteine engineered antibodies may be covalently attached to a capture label, a detection label, a drug moiety, or a solid support.

公开(公告)号：US20200087415A1

公开(公告)日：2020-03-19

申请号：US16383270

申请日：2019-04-12

Applicant: Genentech, Inc.

Inventor： Nicholas J. Armstrong ,  Mayumi N. Bowen ,  Yuh-Fun Maa

IPC: C07K16/40 ,  A61K9/10 ,  A61K9/16 ,  A61K9/00 ,  A61K39/395 ,  C07K16/22 ,  C07K16/28 ,  C07K16/32

Abstract: The present application discloses high-concentration monoclonal antibody formulations suitable for subcutaneous administration, e.g. via a pre-filled syringe. In particular, it discloses a formulation comprising a spray dried monoclonal antibody at a concentration of about 200 mg/mL or more suspended in a non-aqueous suspension vehicle where the viscosity of the suspension vehicle is less than about 20 centipoise. Also disclosed are: a subcutaneous administration device with the formulation therein, a method of making the formulation, a method of making an article of manufacture comprising the suspension formulation, use of the formulation in the preparation of a medicament, and a method of treating a patient with the formulation.

公开(公告)号：US20200085965A1

公开(公告)日：2020-03-19

申请号：US16689286

申请日：2019-11-20

Applicant: GENENTECH, INC.

Inventor： Peter DRAGOVICH ,  Zhonghua PEI ,  Thomas PILLOW ,  Jack SADOWSKY ,  Vishal VERMA ,  Donglu ZHANG

IPC: A61K47/68 ,  A61K31/5517 ,  A61P35/00

Abstract: The invention relates generally to pyrrolobenzodiazepine monomer and dimer prodrugs having a glutathione-activated disulfide prodrug moiety, a DT-diaphorase-activated quinone prodrug moiety or a reactive oxygen species-activated aryl boronic acid or aryl boronic ester prodrug moiety. The invention further relates to pyrrolobenzodiazepine prodrug dimer-antibody conjugates.

公开(公告)号：US10591481B2

公开(公告)日：2020-03-17

申请号：US15336081

申请日：2016-10-27

Applicant: GENENTECH, INC.

Inventor： Linda Orren ,  Aaron Miller ,  Xiaoqing Jia ,  Pin Yee Wong

IPC: G01N33/53 ,  G01N33/573 ,  G01N33/542 ,  C12Q1/37

Abstract: Methods of measuring the activity of Factor D, the key driver in the activation of the alternative complement pathway, methods of determining the potency of Factor D inhibitors, and methods of screening for Factor D inhibitors are provided.

公开(公告)号：US10570192B2

公开(公告)日：2020-02-25

申请号：US15718876

申请日：2017-09-28

Applicant: Genentech, Inc.

Inventor： Eric J. Brown ,  Martine Darwish ,  John Flygare ,  Wouter Hazenbos ,  Byoung Chul Lee ,  Sophie M. Lehar ,  Sanjeev Mariathasan ,  John Hiroshi Morisaki ,  Thomas H. Pillow ,  Leanna Staben ,  Richard Vandlen ,  Klaus Koefoed ,  Magnus Strandh ,  Peter S. Andersen

IPC: C07K16/12 ,  A61K39/40 ,  A61K31/5386 ,  A61K45/06 ,  A61K31/4025 ,  A61K47/68

Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.

公开(公告)号：US20200055928A1

公开(公告)日：2020-02-20

申请号：US16371464

申请日：2019-04-01

Applicant: AC Immune S.A. ,  Genentech, Inc.

Inventor： Andrea Pfeifer ,  Maria Pihlgren ,  Andreas Muhs ,  Ryan Watts

IPC: C07K16/18 ,  G01N33/68

Abstract: The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.